Brief: Neurogene And Neoleukin Announce Definitive Merger Agreement

Neurogene

18/07/2023 11:33

July 18 (Reuters) - Neoleukin Therapeutics Inc  NLTX.O :
    * NEUROGENE AND NEOLEUKIN ANNOUNCE DEFINITIVE MERGER
AGREEMENT
    * NEOLEUKIN THERAPEUTICS INC - COMBINED COMPANY IS EXPECTED
TO
HAVE A CASH BALANCE OF APPROXIMATELY $200 MILLION AT CLOSE
    * NEOLEUKIN THERAPEUTICS INC - CASH EXPECTED TO FUND
COMBINED
COMPANY INTO 2H:26
    * NEOLEUKIN THERAPEUTICS INC - PROPOSED MERGER TO CREATE
NASDAQ-LISTED BIOTECH CO
    * NEOLEUKIN THERAPEUTICS - COMBINED CO IS EXPECTED TO
OPERATE
UNDER NAME NEUROGENE INC. AND TRADE ON NASDAQ CAPITAL MARKET
UNDER TICKER SYMBOL "NGNE"
    * NEOLEUKIN THERAPEUTICS INC - COMBINED COMPANY WILL BE LED
BY
RACHEL MCMINN,  CHIEF EXECUTIVE OFFICER OF NEUROGEN
    * NEOLEUKIN THERAPEUTICS INC - PRE-MERGER NEOLEUKIN
STOCKHOLDERS
ARE EXPECTED TO OWN APPROXIMATELY 16% OF COMBINED COMPANY
    * NEOLEUKIN THERAPEUTICS INC -  PRE-MERGER NEUROGENE
STOCKHOLDERS
ARE EXPECTED TO OWN ABOUT 84% OF COMBINED COMPANY
    * NEOLEUKIN THERAPEUTICS INC - UPON CLOSING OF PROPOSED
TRANSACTION, NEOLEUKIN THERAPEUTICS, INC., WILL BE RENAMED
NEUROGENE INC

Source text for Eikon:  ID:nGNX31cHSH 
Further company coverage:  NLTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))